Trial Profile
An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Rich Tumors of Bone
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Aneurysm; Bone cancer; Bone cysts; Cartilage disorders; Giant cell tumours; Granuloma
- Focus Therapeutic Use
- Acronyms NGCTB
- 02 Nov 2023 Status changed from recruiting to discontinued, according to Results published in the Oncologist.
- 02 Nov 2023 Results published in the Oncologist
- 09 Aug 2021 This trial has been discontinued in France, according to European Clinical Trials Database record.